Loargys
Loargys ingredients
| Active ingredient | Strength |
|---|---|
| Pegzilarginase | 5 mg/mL, 2 mg/.4mL |
What Loargys is used for
The FDA lists the approved uses on the official label (below). In the EU, pegzilarginase is approved as Loargys for:
Loargys is indicated for the treatment of arginase 1 deficiency (ARG1 D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Loargys
- Generic name
- Pegzilarginase-nbln
- Made by
- Immedica Pharma US Inc.
- Forms
- Injection
- Given
- Intravenous, Subcutaneous
- FDA approval
- Biologic licence (BLA) BLA761211
- On the US market since
- 2026
Official information
- Loargys prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Pegzilarginase-nbln)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Loargys?
Loargys (Pegzilarginase-nbln) is a specialist medicine made by Immedica Pharma US Inc., approved by the US FDA.
What are the ingredients of Loargys?
Loargys contains Pegzilarginase (5 mg/mL, 2 mg/.4mL).
Is Loargys approved in Europe?
The same active substance is approved in the EU as Loargys.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA